| |
|
|
|
GTCbio, Philadelphia, PA
Mar 5-7, 2008
Day 1, Wednesday, March 5, 2008
1:30
Registration
2:25
Welcome and Opening Remarks
Session I - New Technologies in Anti-Infectives - Part I
2:30
Marc Mittelman
Vice President, Research & Development, Cernofina
3:00
Dawn Eringis
Vice President, Business Development, PolyMedix
3:30
Mark Alfenito
Executive Vice President, Corporate Development, Kalobios
4:00
CB Rao
Deputy Managing Director, Orgenus Pharma, Inc.
4:30
Rodger Novak
Chief Operating Officer, Nabriva Therapeutics
5:00
Fludase: Reshaping the Management of Influenza-Like Illness; A Novel Mechanism Helps More Doctors to do the Right Thing
David Wurtman, Vice President, Corporate Development, NexBio, Inc.
5:30
Poster Session & Networking Reception
Day 2, Thursday, March 6, 2008
7:00
Registration & Breakfast
7:55
Welcome and Opening Remarks
[KEYNOTE PRESENTATION]
8:00
A Vaccine Renaissance: New Vaccines for the World
John W. Shiver, Vice President, Worldwide Basic Research Franchise Head, Vaccines, Merck and Co., Inc.
Session II - Current Models of R&D Collaboration - Part I
8:45
The Novartis / Human Genome Sciences Albuferon Alliance - Key Success Factors in Driving Successful Biotech / Big Pharma Alliances
Mark Coflin, Global Exec. Dir., IDTI Alliance Mgmt, Novartis Pharmaceuticals
Corporation
Margery B. Fischbein, Vice President, Business Development & Strategic Planning, Human Genome Sciences
9:30
Replenishing the GSK Infectious Disease R&D Pipeline Using Innovative Deals Structures with Strategic Collaborators
Damien McDevitt Ph.D., Director, Business Development, Infectious Diseases CEDD/CEEDD, & World Wide Business Development, GlaxoSmithKline
10:00
Networking & Refreshment Break
10:30
Biota-Boehringer Ingelheim: Making the Right Deal: It’s Not Just About the Money
James Chafouleas, Director, Global Licensing – Virology, Boehringer Ingelheim
Leigh Farrell, Vice President, Business Development, Biota
11:15
Opportunitistic Partnerships in Infectious Diseases - What Big Pharma are Looking For
Douglas Pon, Assistant Vice President, Vaccine Licensing Global Business Development, Wyeth
[PANEL DISCUSSION]
11:45
Developing Partnerships with Big Pharma
12:30
Lunch
Session III - New Pathogen Challenges
1:30
Overview of the Antibacterial Pipeline and Future Areas of Opportunity, 2008
Danielle Drayton, Ph.D., Senior Analyst, Decision Resources
2:00
Multi-Resistant Pseudomonas and Acinetobacter - Challenges and Perspectives
Malcolm Page, Head, Discovery Biology, Basilea Pharmaceuticals
2:30
Genetic Determinants of Tetracycline Resistance and their Occurrence in Escherichia Coli Isolates from the Pivotal Tigecycline Phase 3 Clinical Trials
Hal Jones, Ph.D., Principal Research Scientist II, Wyeth
3:00
Networking and Refreshment Break
3:30
Clostridum Difficile Infection: A Slumbering Giant Awakened?
Glenn Tillotson, Ph.D., Executive Director of Scientific Affairs, Replidyne, Inc.
4:00
Your ‘Plan B’ When All Else Fails? Another Alternative for Your Anti-Infective Compounds
Paul A. Stewart, Manager, Global Business Development, Elanco Animal Health Division, Eli Lilly and Company
[PANEL DISCUSSION]
4:30
Investment Opportunities in the Anti-Infectives Space
Panelists:
Eric C. Meltzer, Managing Director, Curtis Financial Group (Moderator)
Lisa Gray, Managing Partner, Phoenix IP Ventures
Jennifer H. Hartt, Director of Investments, Life Sciences, Investment Group,
Ben Franklin Technology Partners
Gary Patou, Executive Partner, MPM Capital
5:15
Poster Session & Networking
Top of the page
Day 3, Friday, March 7, 2008
7:30
Continental Breakfast
7:55
Chairperson’s Review of Day One
Session IV - Current Models of R&D Collaboration - Part II
8:00
Collaborating with Public-Private Partnerships: The Global Alliance for TB Drug Development
Gerald Siuta, Head of Business Development, Global Alliance for TB Drug Development
8:30
R&D Externalization Strategies
Jacques Dumas, Associate Director, Infection Chemistry, Astra Zeneca R&D
Session V - Future of Infectious Disease Therapeutics
9:00
Making the Golden Goose - How to Obtain and Manage Intellectual Property that Maximizing the Value of Your Deal.
Mike Fuller, Knobbe Martens Olson & Bear
9:30
Regulatory Approval of Antibacterial Drugs: New Science or New Agenda?
Roger M. Echols, M.D., Chief Medical Officer, Replidyne, Inc.
10:00
Networking and Refreshment Break
10:30
Positioning Antibacterials within the Hospital and Community Markets amid Regulatory Changes and Continuing Uncertainty
Dennis Molnar, M.B.A., Vice President, Corporate Development, Paratek Pharmaceuticals
11:00
Combination Therapy / Dual Mechanism Agents
Michael Dudley, Vice President of Drug Development, Mpex Pharmaceuticals
[PANEL DISCUSSION]
11:30
Future of Infectious Disease Therapeutics (cont..)
12:15
Luncheon
Session VI - New Technologies in Anti-Infectives - Part II
1:15
Targeted Molecular Immunogens (Tarmogens®)/ Harnessing Cellular Immunity for the Treatment of Infectious Disease
David Apelian, Chief Medical Officer, Globeimmune
1:45
Oritavancin, a Potent Lipo-Glycopeptide with Unusual Pharmacokinetic Properties that may Allow Single or Infrequent Dosing Schedules
Thomas Parr, Chief Scientific Officer, Targanta
2:15
Hepatitis B Vaccine: Hepislav
Michael S. Ostrach, Chief Business Officer, Dynavax Technologies Corporation
2:45
Kim Morse, Acambis
3:15
Conference Concludes
|
|
|
|
|
|
|
|
Organized by:
|
|
Nina Tran |
|
|
Invited Speakers:
|
|
Visit our web to see invited speakers!
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
February, 2008
|
|
|
|
|
|
|
|
Registration:
|
|
Register 2, the 3rd goes FREE - Register Now!
20% off if you register by January 5, 2008.
|
|
|
E-mail:
|
|
nina.tran@gtcbio.com
|
|
|
|
|
|
|
|
|